Abstract: Objective: To assess the efficacy and safety of treating pterygia by photodynamic therapy (PDT) with verteporfin (Visudyne((R))). Materials and Methods: Ten consecutive patients with primary, recurrent, or secondary pterygium, refusing excisional surgery, were treated with a 689-nm laser delivered directly onto the pterygium after verteporfin infusion. Postoperative outcome was followed clinically and photographically for a minimum of 3 months. Results: Successful photothrombosis of pterygium vascularization was obtained immediately after treatment in all cases. After I month, revascularization of pterygia was observed in 70% of cases, and treatment was repeated after a 3-month interval. Regression or stabilization of pterygia was manifested by a scarring reaction of the corneal apex with complete or partial disappearance of vascularity. No relevant side effects were observed in our series. Conclusion: PDT with verteporfin is a safe procedure to arrest the growth of pterygia. It is indicated for patients with a low- or medium-grade pterygium that refuse a surgical approach, however, multiple sessions may be required.
Photodynamic therapy of pterygium with verteporfin: a preliminary report
FOSSARELLO, MAURIZIO;PEIRETTI, ENRICO;ZUCCA, IGNAZIO ALBERTO;PERRA, MARIA TERESA;
2004-01-01
Abstract
Abstract: Objective: To assess the efficacy and safety of treating pterygia by photodynamic therapy (PDT) with verteporfin (Visudyne((R))). Materials and Methods: Ten consecutive patients with primary, recurrent, or secondary pterygium, refusing excisional surgery, were treated with a 689-nm laser delivered directly onto the pterygium after verteporfin infusion. Postoperative outcome was followed clinically and photographically for a minimum of 3 months. Results: Successful photothrombosis of pterygium vascularization was obtained immediately after treatment in all cases. After I month, revascularization of pterygia was observed in 70% of cases, and treatment was repeated after a 3-month interval. Regression or stabilization of pterygia was manifested by a scarring reaction of the corneal apex with complete or partial disappearance of vascularity. No relevant side effects were observed in our series. Conclusion: PDT with verteporfin is a safe procedure to arrest the growth of pterygia. It is indicated for patients with a low- or medium-grade pterygium that refuse a surgical approach, however, multiple sessions may be required.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
